Related Experiment Video

Updated: Aug 13, 2026

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
08:27

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology

Published on: March 24, 2015

A monoclonal antibody to the human leukocyte adhesion molecule intercellular adhesion molecule-2. Cellular

P Nortamo1, R Salcedo, T Timonen

  • 1Department of Biochemistry, University of Helsinki, Finland.

Journal of Immunology (Baltimore, Md. : 1950)
|April 15, 1991
PubMed

Insights

Researchers developed a novel antibody targeting intercellular adhesion molecule-2 (ICAM-2). This antibody binds to ICAM-2, inhibiting cell adhesion and offering potential for therapeutic applications in inflammatory diseases.

Area of Science:

  • Immunology
  • Molecular Biology
  • Cell Biology

Background:

  • Intercellular Adhesion Molecule-2 (ICAM-2) is a cell surface glycoprotein involved in cell adhesion.
  • Understanding ICAM-2's function requires specific antibodies for research and potential therapeutic development.

Purpose of the Study:

  • To generate and characterize a monoclonal antibody (mAb) against human ICAM-2.
  • To investigate the binding properties and functional effects of the generated anti-ICAM-2 antibody.

Main Methods:

  • Polymerase chain reaction (PCR) synthesis of ICAM-2 DNA.
  • Expression of a protein A-ICAM-2 fusion protein in Escherichia coli.
  • Immunization with fusion protein to produce mAb, followed by selection using immunofluorescence and Western blotting.

Main Results:

  • A novel mAb, 6D5, was successfully generated against ICAM-2.
  • The antibody recognized a 55,000 m.w. glycoprotein on surface-labeled cells and reacted in Western blots.
  • Flow cytometry revealed antibody reactivity with various cell types, including B cells, endothelial cells, and Con A-stimulated mononuclear cells.
  • The antibody specifically bound to the NH2-terminal domain of ICAM-2 and inhibited CD11/CD18-dependent cell adhesion.

Conclusions:

  • The 6D5 mAb is a specific and functional antibody targeting human ICAM-2.
  • The antibody's ability to inhibit cell adhesion suggests potential roles in modulating immune responses and inflammatory processes.

More Related Videos

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

A Flow Cytometry-Based High-Throughput Technique for Screening Integrin-Inhibitory Drugs04:15

A Flow Cytometry-Based High-Throughput Technique for Screening Integrin-Inhibitory Drugs

Published on: February 2, 2024

Related Concept Videos

Cell Adhesion Molecules - Types and Functions01:20

Cell Adhesion Molecules - Types and Functions

Cell adhesion molecules (CAMs) are pivotal to multicellularity and the coordinated functioning of tissues and organ systems. They enable physical interactions between cells and provide mechanical strength to tissues. They also function as receptors for signal transmission across the plasma membrane. The CAMs are broadly classified into four families - integrins, cadherins, selectins, and immunoglobulin-like CAMs (IgCAMs).
CAM Families
The Integrin family of proteins is primarily  involved in a...
Immunoglobulin-like Cell Adhesion Molecules01:31

Immunoglobulin-like Cell Adhesion Molecules

Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.